



Published in final edited form as:

Neurobiol Aging. 2015 March ; 36(3): 1496–1504. doi:10.1016/j.neurobiolaging.2014.12.004.

Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent

Miranda E. Orr¹, Valentina R. Garbarino¹, Angelica Salinas¹, and Rochelle Buffenstein^{1,#}

¹Department of Physiology and The Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio. San Antonio, TX

Abstract

Tau protein is primarily expressed in neuronal axons and modulates microtubule stability. Tau phosphorylation, aggregation and subcellular mislocalization coincide with neurodegeneration in numerous diseases, including Alzheimer's disease [AD]. During AD pathogenesis, tau misprocessing accompanies A β accumulation; however, AD animal models, despite elevated A β , fail to develop tauopathy. To assess whether lack of tau pathology is linked to short lifespan common to most AD models, we examined tau processing in extraordinarily long-lived, mouse-sized naked mole-rats (NMR; ~32 years), which express appreciable levels of A β throughout life. NMRs, like other mammals, displayed highest tau phosphorylation during brain development. While tau phosphorylation decreased with aging, unexpectedly adult NMRs had higher levels than transgenic mice overexpressing mutant human tau. However, in sharp contrast with the somatodendritic accumulation of misprocessed tau in the transgenic mice, NMRs maintain axonal tau localization. Intriguingly, the adult NMR tau protein is 88kDa, much larger than 45-68kDa tau expressed in other mammals. We propose that this 88kDa tau protein may offer exceptional microtubule stability and neuroprotection against lifelong elevated A β .

Keywords

Tau; phosphorylation; Alzheimer's disease; naked mole-rat; aging; animal model

1. Introduction

The microtubule associated protein tau regulates several distinct neuronal processes including microtubule nucleation, polymerization, polarity, dynamics, spacing and bundling. Tau's functional importance becomes evident in patients with microdeletions in the coding gene, MAPT. While exceedingly rare, these mutations result in mental retardation and

[#]To whom correspondence should be addressed: ROCHELLE BUFFENSTEIN, Ph.D., Professor, Department of Physiology and The Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, 15355, Lambda Drive, San Antonio, Texas 78245, buffenstein@uthscsa.edu, Phone: 210 562-5062.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures

The authors state that they have nothing to disclose, and that there are no potential conflicts of interest.

craniofacial abnormalities (Rovelet-Lecrux and Campion, 2012). Correspondingly, mice homozygous for *Mapt* deletion display long term-potential impairments resulting in cognitive deficits (Ahmed, et al., 2014). Far more frequently, tau negative regulation occurs through post-translational phosphorylation (Lindwall and Cole, 1984), and tau misprocessing, initiated primarily through hyperphosphorylation, coincides with neurodegeneration in a variety of disorders (e.g., Pick's disease, argyrophilic grain disease, progressive supranuclear palsy, frontotemporal dementia and chronic traumatic encephalopathy as well as Alzheimer's disease (AD)) (Spillantini and Goedert, 2013). Several studies have revealed exacerbated pathology in respective animal models upon genetically ablating *Mapt* including enhanced tauopathy (Ando, et al., 2011); lysosomal dysfunction (Pacheco, et al., 2009); Parkinsonism (Lei, et al., 2012) as well as A β -associated axonal degeneration (Dawson, et al., 2010) underscoring the importance of functional tau during situations of neurotoxic stress.

The vast majority of patients afflicted with tauopathies develop the diseases sporadically, with age being the greatest risk factor. Incongruously, the most common animal models for these diseases are short-lived mice that do not naturally develop tauopathy, possibly due to their short-lifespan. To overcome this shortcoming, induction of pathology is accomplished through genetic overexpression of mutant human gene variants. Fully penetrant AD-inducing mutations, while exceedingly rare accounting for <2% of all AD cases, occur in genes encoding proteins responsible for the accumulation of toxic, aggregation prone A β ₁₋₄₂. The concomitant misprocessing of tau, cognitive decline, behavioral changes, neuronal loss and brain atrophy suggests that A β , alone, may drive AD. Discovery of these familial AD mutations engendered the "A β hypothesis" (Hardy and Higgins, 1992) that posits A β accumulation is necessary and sufficient to drive AD pathogenesis and tauopathy. Many AD models expressing elevated A β display cognitive impairments, but do not develop appreciable tau pathology unless multiple transgenes (e.g. mutant human tau, (Oddo, et al., 2003)) are also expressed and neurodegeneration seldom occurs (Wirhth and Bayer, 2010). Strikingly, despite successful pharmacological amelioration of AD pathology and attenuation of cognitive decline over 300 times in such animal models, none of these promising preclinical findings have translated into effective and safe human therapies (Zahs and Ashe, 2010). The reasons, while not entirely clear, may reflect the modeling of the extremely rare heritable diseases in short-lived mammals, rather than addressing the more common sporadic nature of tauopathy and the use of model systems with lifespans long enough to track pathogenesis.

Recently we discovered naturally expressed, high levels of A β in the brains of the naked mole-rat (NMR, *Heterocephalus glaber*), the longest lived rodent known (Edrey, et al., 2013). These mouse-sized rodents defy maximum lifespan predictions by living ~5 times longer than expected based on their body size and ~8 times longer than similar sized mice. With a maximum lifespan of >30 years, they offer an exceptional perspective to investigate age-associated diseases. Many NMRs express higher brain A β levels than do 3xTg-AD mice (Edrey, et al., 2013), a well-characterized mouse model of AD pathology genetically manipulated to express high levels of this toxic peptide (Oddo, et al., 2003). The NMR A β peptide differs from that of human A β by one amino acid, but both human and NMR A β exert similar neurotoxicity to mouse cortical neurons *in vitro* (Edrey, et al., 2013). NMRs,

however, do not develop manifest plaques and seemingly maintain neuronal integrity. We wondered whether tau metabolism remained properly regulated despite >30 years of high levels of A β peptide. Specifically we investigated whether NMR tau protein is similar to human tau (e.g., sequence, size, expression, phosphorylation), how it changes with age, and whether lifelong elevated levels of A β alter tau misprocessing in NMRs. We assessed levels of total tau, phosphorylated tau and known tau kinases throughout the NMR 30-year lifespan and compared adult brain histology to that of well-characterized 3xTg-AD mice.

2. Materials and Methods

2.1 Animals

Animal procedures were carried out in adherence to NIH, Federal, State, and Institutional guidelines at University of Texas Health Science Center San Antonio (University of Texas Health Science Center at San Antonio UTHSCSA; protocol #07123).

2.2 Tissue collection

Brains from 38 naked mole-rats (< 1 year) and 24 (>1 year) were collected. Animals were anesthetized by isoflurane inhalation then transcardially perfused with ice-cold PBS. Brains were immediately harvested, weighed and sagittally bisected. One hemisphere was drop fixed in 10% zinc formalin for 48 hours, then transferred to PBS containing 0.02% sodium azide and stored at 4°C until further histological processing. The other hemisphere was snap frozen in liquid nitrogen and stored at -80°C for future biochemical analyses.

2.3 Tissue Homogenization

For biochemistry, frozen hemibrains (minus cerebellum and brain stem) were slightly thawed on ice and mechanically homogenized with dounce and pestle in ice-cold Buffer H (10mM Tris HCl pH 7.4, 1mM EGTA, 0.8M NaCl, 10% sucrose) containing complete protease inhibitor (Roche, Basel, Switzerland) with or without phosphatase inhibitors (Invitrogen, Carlsbad, CA). Brain homogenates were centrifuged 14,000 rpm for 20 minutes at 4°C. The supernatant was used for all further capillary electrophoresis. Protein concentration was determined using BCA assay (Pierce, Rockford, IL).

2.4 Capillary Electrophoresis Immunoassay

Capillary electrophoresis immunoblotting, or Simple Western analyses, were performed using the SimonTM and WesTM platforms for tau and tau kinase levels, respectively, according to the manufacturer's protocol (ProteinSimple Santa Clara, CA). This state of the art technology is considered more sensitive and quantitative than traditional Western blot immunoblotting, generating highly reproducible electropherograms with precise peaks and facilitating accurate molecular weight assessments (Creamer, et al., 2014, Nguyen, et al., 2011). In brief, brain homogenate was diluted to 6 μ g (for SimonTM) or 1 μ g (for WesTM) in sample buffer and added to a master mix containing dithiothreitol (DTT) and fluorescent molecular weight marker then heated at 95°C for 5 min. The chemiluminescent substrate, HRP-conjugated secondary antibody, primary antibody, blocking reagent, samples, and separation and stacking matrices were dispensed into a 384-well plate. After plate loading, the separation electrophoresis and immunodetection steps took place in the capillary system

and were fully automated. Simple Western analysis is carried out at room temperature, and instrument default settings were used. Primary antibodies used: rabbit anti- total and phospho-GSK3 β Ser⁹, total and phospho-ERK1/2 Thr^{202/204} and Thr^{185/187}, Cdk5, p35, and mouse anti-Tau46 (1:50) and mouse anti-GAPDH (1:100) (Cell Signaling, Danvers, MA). Dilutions of anti-tau antibodies as follows: Tau1 (1:100); RD3, RD4 and Tau5 (1:50) (Millipore, Billerica, MA); mouse anti-CP13 and PHF1 (1:10) (generous gifts from Peter Davies); mouse anti-HT7 (1:50) (Pierce, Rockford, IL). Recombinant human tau was purchased (rPeptide, Bogart, GA). All antibodies were diluted with antibody diluent (ProteinSimple, Santa Clara, CA). The digital image was analyzed with Compass software (ProteinSimple, Santa Clara, CA), and the quantified data of the detected protein were reported as molecular weight. Protein densitometry was calculated by dividing the area under the curve of each protein of interest by area under the curve of GAPDH loading control.

2.5 Phosphatase Assay

For removing post-translational phosphorylation, brain homogenates were suspended in 0.8 $\mu\text{g}/\mu\text{L}$ of NEBuffer 3 and incubated with 20U/ μL of calf intestinal phosphatase (CIP) (New England Biolabs, Ipswich, MA) for 60 minutes at 37°C. CIP treated samples were compared to samples incubated in NEBuffer 3 without CIP.

2.6 Immunohistochemistry

Zinc formalin fixed tissues were sectioned (30 μm thick) using a sliding vibratome, and stored in 0.02% sodium azide in PBS until immunostaining was conducted. The endogenous peroxidase activity was quenched with 3% H₂O₂ in 10% methanol for 30 minutes. Tissue was incubated overnight at 4°C with corresponding primary antibody. Sections were washed in tris buffered saline and incubated in biotinylated secondary antibody for 1 hour at 20°C. Sections were developed with diaminobenzidine substrate using the avidin-biotin horseradish peroxidase system (Vector Labs, Burlingame, CA, USA). Primary antibodies: HT7 (1:3000) and CP13 (1:2000). Images were obtained with a Zeiss camera. For each antibody, all tissues were immunostained simultaneously to eliminate batch-to-batch variability in antibody concentrations, incubation times, or chromogen exposure. Similarly, all images were acquired using identical settings to prevent light, exposure or other subtle microscopy differences. As such, relative differences in immunostaining at the various ages can be compared with confidence.

2.7 Statistics

All data were analyzed using GraphPad Prism version 6.0c for Mac OS X, GraphPad Software, San Diego California, USA, www.graphpad.com/. Data were analyzed by one-way analysis of variance.

2.8 Sequence Alignment

Known human tau protein sequences and predicted naked mole-rat were acquired from NCBI. Clustal Omega was used for sequence alignment.

3. Results

3.1 NMR tau protein sequence is highly similar to human tau

Human microtubule associated protein tau (MAPT) is a single copy gene that undergoes alternative splicing to generate several unique splice variants; six splice variants are expressed in the adult brain (Goedert, et al., 1989a, Goedert, et al., 1989b). While no information regarding NMR tau protein is available, the NMR genome has been sequenced (Kim, et al., 2011) and predicted protein sequences are accessible through NCBI and the Naked Mole-Rat Genome Resource 2014 (<http://naked-mole-rat.org>). The NMR brain, like human brain, generates two *Mapt* transcripts, 2 and 6kb (Goedert, et al., 1989a, Goedert, et al., 1989b), with several projected tau proteins (Kim, et al., 2011; <http://naked-mole-rat.org>). NMR *Mapt* isoform X2 with a predicted amino acid length of 446, is most similar in identity and length to the longest human brain tau splice variant, 441 amino acid isoform 4R2N. Protein alignment comparison illustrates high homology between species (95% identical), and 100% identity at the functional microtubule-binding domain (Fig. 1). Additionally, the comparison indicates high conservation of NMR tau at antibody epitopes commonly used to study human tau including total tau antibodies: HT7, Tau5, Tau46; microtubule binding domains: RD3 and RD4; phospho-tau: CP13 and PHF1; and non-phospho-tau: Tau1. Immunoblotting with these antibodies revealed that NMR tau protein is highly immunoreactive to antibodies against the functional microtubule binding domains, middle and C-terminus as indicated by strong immunoreactivity to RD3, RD4, HT7, Tau5 and Tau46, respectively. Strikingly, the NMR protein is dramatically larger than tau expressed in adult wild type mice or transgenic human tau expressing mice (Fig. 2A). The prominent adult NMR tau protein is ~88kDa, which is much larger than the heaviest human tau protein band migrating at ~72kDa (Fig. 2A).

3.2 NMR tau undergoes a progressive increase in molecular weight during development

Since differential tau processing occurs between development and adulthood in other mammals (Goedert, et al., 1989b, Himmler, et al., 1989), we assessed the developmental and aging profile of NMR total tau using capillary electrophoresis (CE). This highly reproducible quantitative technology facilitates the precise discernment of protein molecular weight as well as protein levels in myriad cell lines and tissues including brain (Beccano-Kelley, et al., 2014, Creamer, et al., 2014, Nguyen, et al., 2011). At birth NMR brain tau appears as doublet bands migrating at 62 and 72kDa. These proteins persist through 2 weeks of age with the 72kDa protein becoming more abundant. Around 3 weeks of age, the lower 62kDa band disappears and the 72kDa band becomes the prominent tau protein expressed. At 3 months of age, expression of higher molecular weight tau protein begins to occur with the emergence of an 88kDa band and by 1 year of age this becomes the predominant tau protein (Fig. 2B, C).

3.3.1 NMR tau expression decreases with age—To better understand how levels of total tau are affected by age and the contribution of phosphorylation to the molecular weight shift observed, we examined levels of total and phosphorylated tau throughout the NMR lifespan. Levels of total tau are highest during postnatal development and then significantly decrease by one month of age (ANOVA, $p = 0.0184$) where a constant expression level is

maintained for the next 2 years of life. A significant decrease in total tau expression occurs in the 7-10 year-old cohort (ANOVA, $p = 0.0033$) and this level is maintained through the rest of mid-late adulthood (Fig. 3A-B). Immunohistochemical (IHC) analysis of cortical brain tissue compliments the CE results whereby high protein expression occurs through 3 weeks of age and lower total tau levels are expressed in the adult brain (Fig. 3C).

3.3.2 Tau phosphorylation levels decrease with age in cortical and hippocampal brain tissue

—During development the nervous system requires a dynamic cytoskeleton permissive to axonal migration, neurite outgrowth and extension. To facilitate this fluid cytoskeleton, tau protein is heavily phosphorylated allowing for rapid dissociation and microtubule disassembly (Brion, et al., 1993). Human fetal tau contains 7 moles of phosphate per mole of protein, which greatly contrasts to the healthy adult brain with only 1-3 moles of phosphate per mole of tau (Kenessey and Yen, 1993). To determine whether NMRs express measurable levels of phosphorylated tau, we conducted CE and IHC on NMR brains across their 30-year lifespan. The amount of NMR tau phosphorylated at Ser^{396/404}, epitopes phosphorylated during development and AD pathogenesis, was determined by probing samples with the PHF1 antibody. NMR brains express high amounts of PHF1 immunoreactive protein that significantly depends on age (Fig. 4. ANOVA, $p < 0.0001$). The highest level of phospho-tau protein expression occurs during early development. Neonate brains contain 42.9% more phospho-tau than 3-month-old NMRs (ANOVA, $p = 0.0003$). PHF1 immunoreactivity drops significantly, nearly half (44.9%), again by 6 months of age (ANOVA, $p = 0.0152$). Phosphorylated tau levels remain constant throughout the remainder of the NMR lifespan suggesting this age, 6 months, may represent a transition to a mature adult brain (Fig. 4A-B).

To better determine the contribution of tau phosphorylation on the developmental molecular weight shift, we treated brain homogenates with alkaline phosphatase to promote dephosphorylation. We compared 2-week-old and 2-year-old NMRs since tau protein from these ages greatly differs in size and appropriately represent development and adulthood, respectively (Fig. 2B). We compared untreated and CIP treated brain homogenates to recombinant human tau 4R2N. A shift in total tau molecular weight occurs with phosphatase treatment (Fig. 4C, HT7) in both 2 week-old and 2 year-old samples suggesting that tau phosphorylation contributes to molecular weight in both ages, and corroborates the PHF1 phosphorylation data (Fig. 4A). We used an antibody specific to non-phosphorylated tau, Tau1, as an additional control to ensure efficacy of the phosphatase treatment. Indeed, Tau1 immunoreactivity dramatically increased upon phosphatase treatment and coincided with the absence of PHF1 immunoreactivity. Notably, 2-year-old NMR tau is larger than 2-week-old NMR tau even after dephosphorylation indicating the difference in molecular weight is not entirely due to phosphorylation (Fig. 4C). Further, dephosphorylated NMR tau is much larger than recombinant human tau 4R2N indicating molecular weight differences between species extend beyond post-translational phosphorylation (Fig. 4C).

To evaluate the distribution of tau phosphorylation throughout the NMR brain, we conducted IHC with the phospho-specific antibody, CP13, which recognizes tau phosphorylated at Ser²⁰²/Thr²⁰⁵, an epitope phosphorylated during development and also during early stages of early AD pathogenesis. As seen with CE, the highest levels of phosphorylation occur early

in development in both the cortex as well as hippocampal CA1 (Fig. 4D). Additionally, a dramatic decrease occurs around 6 months of age and this lower level of phosphorylation is maintained throughout the next decades of life similar to results with total tau and PHF1 tau antibodies.

3.4 Protein levels of tau kinase increase with age

During brain development axons actively migrate to seek out and build appropriate neuronal circuits; this requires a dynamic microtubule cytoskeleton with phospho-tau mechanistically achieved by active tau kinases. To evaluate tau kinase expression level and regulation throughout development and adulthood, we determined the relative amounts of total GSK3 β , Cdk5, and ERK2 tau kinases. Each of these well-characterized kinases is well recognized for their importance in physiological brain development as well as pathogenic neurodegenerative cascades. Further we immunoprobed for kinase regulators to gain mechanistic insight into kinase activity. Specifically, we evaluated levels of Cdk5 co-activator, p35, and regulatory phosphorylation of GSK3 β and ERK1/2. We found strong antibody immunoreactivity to total and phosphorylated kinases in NMR brains at all ages; the total and phospho-ERK1/2 antibodies were far more immunoreactive to total and phospho-ERK2 than ERK1. NMRs may preferentially utilize ERK2, and from here forward we discuss ERK2 only. Levels of total Cdk5, p35 and ERK2 did not differ with age. However, total GSK3 β expression levels significantly decreased when animals reached sexual maturity (6-9 months) (Fig. 5A, C). Notably, this decrease in total GSK3 β level correlates well with the decrease in total and phospho-tau indicating an important milestone in brain maturation for NMRs (Fig. 3 and 4). Levels of regulatory GSK3 β phosphorylation at Ser⁹ did not decrease significantly until mature adulthood (7 years-old and beyond), which corresponds with the second major decline in total tau expression (Fig. 3). Interestingly, based on body size, NMRs have a predicted lifespan of 7-8 years. The significant decrease in total tau expression and regulatory kinase activity may indicate another critical stage in NMR brain development, maintenance or maturity that we are continuing to explore. Levels of activated ERK2 phosphorylated at Thr^{187/189} do not significantly differ with age except for in the oldest 30-year-old cohort (Fig. 5). Thirty-year-old NMRs are comparable to a supercentenarian humans; while high ERK2 activation did not correlate with elevated phosphorylated tau in these animals, it may have implications in healthy brain aging and is worth exploring.

3.5 Naked mole-rats express significantly more total tau and phospho tau than 3xTg-AD mice

Previously we found that NMRs express higher levels of A β than 3xTg-AD mice. To gain better perspective into the level of total and phospho-tau expression of NMRs, we directly compared them to 3xTg-AD mice. We found that young adult (2-7 yr-old) NMRs expressed ~4x more total tau and phospho-tau than 15-month-old 3xTg-AD mice with manifest pathology (Fig. 6A, B; unpaired t-test, $p < 0.0001$ and $p = 0.0025$, respectively). Transgenic mutant human tau_{P301L} expressed by 3xTg-AD mice becomes hyperphosphorylated and mislocalizes from the axon to the somatodendritic compartment. However, despite higher expression levels of total tau, NMR tau remains appropriately localized in the axon as

evidenced by strong immunoreactivity in mossy fibers indicating maintenance of physiological function (Fig. 6C).

4. Discussion

Tau misprocessing occurs early in disease pathogenesis in numerous neurodegenerative tauopathies. In the most prevalent of these, Alzheimer's disease (AD), A β accrual has been hypothesized to drive tau pathology and downstream neurodegeneration (Hardy and Higgins, 1992). Interestingly, however, neurofibrillary tangles, comprised of hyperphosphorylated tau (phospho-tau), better correlate with AD severity (e.g. cognitive decline, behavioral changes, neuronal loss and brain atrophy) and duration than A β pathology (Arriagada, et al., 1992). With the discovery of high levels of A β (soluble and insoluble) in prenatally long-lived NMRs (Edrey, et al., 2013), we focused on the role of tau protein in their innate resistance to A β neurotoxicity. Our comparison of putative NMR tau protein, derived from the sequenced NMR genome (Kim, et al., 2011), to human tau protein indicated 95% sequence identity (Fig.1). In agreement to the *in silico* prediction, we found that NMR brain homogenates contained protein highly immunoreactive to eight distinct anti-human tau antibodies. While neonatal NMR tau appears similar in size to human tau, a progressive increase in NMR tau molecular weight occurs throughout development resulting in an adult-expressed 88kDa protein remarkably larger than tau protein reported from other species (Fig. 2). We found that NMR tau is phosphorylated at several epitopes throughout life. While the highest levels of tau phosphorylation occur during development, even adult NMRs express higher levels of total and phospho-tau than 15-month-old 3xTg-AD mice with overt tau pathology (Fig. 6). Mechanistically, we found tau kinase activity is tightly regulated throughout the NMR lifespan indicating a physiological role of tau phosphorylation in these animals (Fig. 3-6). Despite high levels of total and phospho-tau levels, NMRs appropriately maintain tau expression within the axonal compartment, which contrasts to the mislocalized somatodendritic tau in 3xTg-AD hippocampal neurons, and suggests sustained physiologic, not pathogenic, NMR tau function.

Neurons undergo many ontogenetic phases including proliferation, migration, fate determination, differentiation, formation of axonal pathways and synaptic connections, all requiring a dynamic cytoskeleton. Tau phosphorylation rapidly alters microtubule stability by decreasing microtubule-binding affinity and helps accommodate dynamic needs of these developing neurons (Biernat, et al., 1993, Bramblett, et al., 1993, Goedert, et al., 1991, Hirokawa, 1994, Lindwall and Cole, 1984). After neurons have completed axonal path-finding, the elaborate and competitive feat to establish appropriate connections, about half of them undergo one final phase of development: degeneration and death (Burek and Oppenheim, 1996, Oppenheim, 1991, Yuan, et al., 2003). This counterintuitive, non-pathological, massive neuronal death requires disassembly of microtubules, which is facilitated by heavy tau phosphorylation (Lindwall and Cole, 1984). Accordingly, tau from pre-pubescent developing NMR brains is heavily phosphorylated (Fig. 4). Significantly higher levels of total tau and phospho-tau in the first months of NMR life (Fig. 3 and 4) than adulthood may reflect the overabundance of newly born neurons undergoing axonal migration; the significant decrease through 6 months of age may reflect the final stages of

brain development: formation of neural networks and the normal event of massive neuronal death.

Axons of functionally active, mature neurons of the adult nervous system remain static to preserve the neural pathways and established signaling networks. Correspondingly, tau is not heavily phosphorylated in the adult nervous system. Histological and biochemical assessment revealed that NMRs, like other mammals (Kenessey and Yen, 1993), express less phosphorylated tau in adulthood than in development (Fig. 4). Unlike other rodents, however, NMRs displayed high levels of phospho-tau longer throughout development, between 3-6 months of age, than the 3 weeks observed in mice and rats. This prolonged period of high phospho-tau may reflect the NMR extended developmental period. While mice and rats reach sexual maturity 4-6 weeks of age, NMRs prepubescent period extends through the first 6 months of life. Recent studies suggest that delayed NMR maturation pertains not only to their reproductive system but includes brain development as well as the maintenance of several neotenus traits even into adulthood (Buffenstein, 2001, Peterson, et al., 2012a, Peterson, et al., 2012b). For example, while investigating hypoxia tolerance, a feature common to neonatal brains, NMRs were found to maintain this feature weeks longer than mice (Peterson, et al., 2012a). Compared to hippocampal slices cultured from mice that display an adult-like response to hypoxia by postnatal day 20, NMRs calcium response remains blunted through postnatal day 42. While NMR hypoxia response was abnormal compared to mice at all ages tested, a significant age-related increase occurred between postnatal days 6-20 (Peterson, et al., 2012a), which coincides with the first major change in tau protein size reported here (Fig. 2). To cope with low oxygen availability *in utero*, developing mammalian neonates express an NMDA subunit that is less hypoxia sensitive than adult NMDA receptors, and NMRs retain expression of this neonatal subunit, NR2B, longer than mice (Bickler, et al., 2003). In a separate study stabilizing microfilaments with phalloidin prevented the hypoxia-induced decrease in NMDA receptor function in postnatal day 3-10 rat neurons (Bickler, et al., 2003). This finding not only emphasizes the importance of cytoskeletal stability during hypoxia, possibly for receptor internalization, but also suggests that the tau molecular weight shifts observed here correspond with neuronal maturation milestones in NMR development. The delayed brain development in NMRs may contribute to their extreme longevity, as short-lived animals often are born precocious or with accelerated sexual maturation.

Phosphorylation dramatically alters tau molecular weight. For example, recombinant 4R2N human tau protein has a molecular weight of 45.9kDa, while the heavily phosphorylated pathogenic tau protein extracted from AD patient brains is 72/74kDa (for review (Ozansoy, 2007)). To assess the contribution of phosphorylation on the developmental increase in tau molecular weight we probed brain homogenates with antibodies specific to tau phosphorylation before and after the addition of phosphatase (Fig. 4). NMR tau was immunoreactive to tau phosphorylated at Ser^{396/404}, and phosphatase treatment greatly reduced the molecular weight indicating that NMR tau is heavily phosphorylated in development and adulthood (Fig. 4). However, even phosphatase treated samples displayed an age-dependent difference in molecular weight suggesting that other post-translational modifications may contribute, in part, to the difference in molecular weight (Martin, et al., 2011). Another possibility is that NMRs incorporate unique exons through alternative

splicing that other mammals do not naturally express. Since our assessment of NMR sequence data indicates that NMR *Mapt* brain transcript is similar in length to that of humans (Kim, et al., 2011; <http://naked-mole-rat.org>), we are exploring alternative splicing in development and in aging in our on-going studies.

Kinase dysregulation has catastrophic implications in myriad signaling cascades. In regard to tau metabolism, tau hyperphosphorylation can result in its misfolding, aggregation, decreased solubility and eventual neurodegeneration and dementia in various tauopathies including AD (for review (Martin, et al., 2013) (Cruz and Tsai, 2004, Leroy, et al., 2007, Vogelsberg-Ragaglia, et al., 2001, Wang, et al., 2007)). We have not seen overt brain pathology even in NMRs >20 years old suggesting precise regulatory control of kinases throughout the extraordinarily long NMR lifespan (Edrey, et al., 2013). Here we found stable levels of Cdk5, p35 and ERK2. Further, increased inhibitory GSK3 β phosphorylation at Ser⁹ during development is indicative of regulated activity during this potentially vulnerable period marked by high levels of total GSK3 β (Fig. 5). We did, however, find increased levels of ERK2 phosphorylated at activation loop residues Thr^{185/187} (Fig. 5). It is tempting to speculate that high levels of phospho-ERK2 relate to successful healthy brain aging as this 30-year-old cohort is comparable to supercentenarian humans. Alternately, it may reflect their social status as the colony's eldest members. Indeed, ERK2 activity has been shown to play a crucial role in social, cognitive and social behavior in mice (Satoh, et al., 2011). Additional studies comparing ERK2 phosphorylation between animals of different social hierarchy will help elucidate this possibility.

Previously we compared A β expression levels between NMRs and 3xTg-AD mice. Surprisingly, we found that NMRs expressed higher levels of A β than the genetically engineered AD mouse model (Edrey, et al., 2013). In our current study, we found that NMRs also express higher levels of total and phospho-tau than 3xTg-AD mice (Fig. 6). Though NMR brains contain elevated levels of both AD-associated proteins (A β and phospho-tau) they do not develop manifest A β plaques, neurofibrillary tangle pathology or neuronal loss even in the oldest cohort (30-year-old NMRs). Furthermore, unlike 3xTg-AD hippocampal neurons displaying hyperphosphorylated tau mislocalized to the somatodendritic compartment NMRs appropriately maintained axonal tau localization despite appreciable tau phosphorylation (Fig. 6). These data strongly suggest a physiological relevance for the high levels of phospho-tau in life-long brain maintenance and overall neuronal integrity in this unique mammal. Our results represent a paradigm shift suggesting that high levels of both A β and phospho-tau may indeed be important neural regulators, especially in conditions of high oxidative stress as seen in NMRs (Edrey, et al., 2014) rather than simply biomarkers of a diseased state. Supporting this premise, phospho-tau has been shown to protect against oxidative stress (Lee, et al., 2005) and neuronal apoptosis (Morsch, et al., 1999), and neurons survive decades with tau aggregated neurofibrillary tangles (Li, et al., 2007). Elevated levels of A β and phospho-tau in AD may possibly reflect that protective mechanisms have been overwhelmed as AD takes hold as A β , too, has shown to be neuroprotective in both developing and mature neurons (Giuffrida, et al., 2009) and cerebral interstitial A β levels positively correlate with neurological status (Brody, et al., 2008).

Since most animal species do not naturally develop measurable levels of brain A β or phospho-tau, transgenic mice have been the mainstay of AD research. Sporadic and familial AD, while differing in etiology, have similar pathologies suggesting that they may arise through similar pathogenic mechanisms once initiated. This assumption, while key in modeling aspects of AD, has failed to produce translational therapeutics to AD patients. Furthermore, a recent study clearly indicated differences in tau pathology between mutant and wild type expressed proteins suggesting distinct pathogenic mechanisms between familial and sporadic disease (Dujardin, et al., 2014). Since the vast majority of patients (>98%) do not carry genetic AD mutations, there is a critical need for sporadic animal models to compliment the genetic models currently used. Despite high risk factors for developing AD: insulin resistance (Kramer and Buffenstein, 2004) and high levels of brain oxidative stress (Edrey, et al., 2014), A β (Edrey, et al., 2013) and phosphorylated tau (Fig. 4 and 6), NMRs do not succumb to these toxic insults. Understanding mechanisms utilized by these remarkable long-lived mammals to curtail neurodegenerative disease will provide great insight into protective mechanisms that may translate to maintained brain function in other species, including humans. In this study evaluating NMR tau metabolic changes with age we clearly show that phosphorylated tau is not neurodegenerative, and that the high molecular weight protein offers unique insight into sustained neuronal maintenance.

Acknowledgements

We thank Yael Edrey, Kelly Grimes, Kaitlyn Lewis and Karl Rodriguez for help with tissue harvesting and Megan Smith for the care of the animals. This study was approved by the IACUC at UTHSCSA.

Financial Support This work was supported by the American Federation for Aging Research, the Glenn Foundation and the NIA/NIH AG022891. Miranda Orr is supported by a training grant from the National Institute of Aging (T32AG021890).

References

- Ahmed T, Van der Jeugd A, Blum D, Galas MC, D'Hooge R, Buee L, Balschun D. Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. *Neurobiology of aging*. 2014 doi:10.1016/j.neurobiolaging.2014.05.005.
- Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. *The American journal of pathology*. 2011; 178(2):803–16. doi:10.1016/j.ajpath.2010.10.034. [PubMed: 21281813]
- Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. *Journal of neurochemistry*. 2003; 86(3):582–90. [PubMed: 12859672]
- Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology*. 1992; 42(3 Pt 1):631–9. [PubMed: 1549228]
- Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, Cao L-P, Han H, Tapia L, Farrer MJ, Milnerwood AJ. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. *Frontiers in cellular neuroscience*. 2014; 8:301–11. doi:10.3389/fncel.2014.00301. [PubMed: 25309331]
- Bickler PE, Fahlman CS, Taylor DM. Oxygen sensitivity of NMDA receptors: relationship to NR2 subunit composition and hypoxia tolerance of neonatal neurons. *Neuroscience*. 2003; 118(1):25–35. [PubMed: 12676134]

- Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. *Neuron*. 1993; 11(1):153–63. [PubMed: 8393323]
- Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. *Neuron*. 1993; 10(6):1089–99. [PubMed: 8318230]
- Brion JP, Smith C, Couck AM, Gallo JM, Anderton BH. Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. *Journal of neurochemistry*. 1993; 61(6):2071–80. [PubMed: 8245963]
- Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. *Science*. 2008; 321(5893):1221–4. doi:10.1126/science.1161591. [PubMed: 18755980]
- Buffenstein R. *Ecophysiological Responses of Subterranean Rodents to Underground Habitats. Life Underground, the Biology of Subterranean Rodents*. 2001
- Burek MJ, Oppenheim RW. Programmed cell death in the developing nervous system. *Brain pathology*. 1996; 6(4):427–46. [PubMed: 8944315]
- Creamer JS, Oborny NJ, Lunte SM. Recent advances in the analysis of therapeutic proteins by capillary and microchip electrophoresis. *Analytical methods : advancing methods and applications*. 2014; 6(15):5427–49. doi:10.1039/C4AY00447G. [PubMed: 25126117]
- Cruz JC, Tsai LH. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. *Current opinion in neurobiology*. 2004; 14(3):390–4. doi:10.1016/j.conb.2004.05.002. [PubMed: 15194121]
- Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM, Lynch JR, Laskowitz DT. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. *Neuroscience*. 2010; 169(1):516–31. doi:10.1016/j.neuroscience.2010.04.037. [PubMed: 20434528]
- Dujardin S, Lecolle K, Caillieze R, Begard S, Zommer N, Lachaud C, Carrier S, Dufour N, Auregan G, Winderickx J, Hantraye P, Deglon N, Colin M, Buee L. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. *Acta neuropathologica communications*. 2014; 2(1):14. doi:10.1186/2051-5960-2-14. [PubMed: 24479894]
- Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A, Buffenstein R. Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. *Neurobiology of aging*. 2013; 34(10):2352–60. doi:10.1016/j.neurobiolaging.2013.03.032. [PubMed: 23618870]
- Edrey YH, Oddo S, Cornelius C, Caccamo A, Calabrese V, Buffenstein R. Oxidative damage and amyloid-beta metabolism in brain regions of the longest-lived rodents. *Journal of neuroscience research*. 2014; 92(2):195–205. doi:10.1002/jnr.23320. [PubMed: 24273049]
- Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A. Beta-amyloid monomers are neuroprotective. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2009; 29(34):10582–7. doi:10.1523/JNEUROSCI.1736-09.2009. [PubMed: 19710311]
- Goedert M, Crowther RA, Garner CC. Molecular characterization of microtubule-associated proteins tau and MAP2. *Trends in neurosciences*. 1991; 14(5):193–9. [PubMed: 1713721]
- Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. *Neuron*. 1989a; 3(4):519–26. [PubMed: 2484340]
- Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. *The EMBO journal*. 1989b; 8(2):393–9. [PubMed: 2498079]
- Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992; 256(5054):184–5. [PubMed: 1566067]

- Himmler A, Drechsel D, Kirschner MW, Martin DW Jr. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. *Molecular and cellular biology*. 1989; 9(4):1381–8. [PubMed: 2498649]
- Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. *Current opinion in cell biology*. 1994; 6(1):74–81. [PubMed: 8167029]
- Kenessey A, Yen SH. The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. *Brain research*. 1993; 629(1):40–6. [PubMed: 8287279]
- Kim EB, Fang X, Fushan AA, Huang Z, Lobanov AV, Han L, Marino SM, Sun X, Turanov AA, Yang P, Yim SH, Zhao X, Kasaikina MV, Stoletzki N, Peng C, Polak P, Xiong Z, Kiezun A, Zhu Y, Chen Y, Kryukov GV, Zhang Q, Peshkin L, Yang L, Bronson RT, Buffenstein R, Wang B, Han C, Li Q, Chen L, Zhao W, Sunyaev SR, Park TJ, Zhang G, Wang J, Gladyshev VN. Genome sequencing reveals insights into physiology and longevity of the naked mole rat. *Nature*. 2011; 479(7372): 223–7. doi:10.1038/nature10533. [PubMed: 21993625]
- Kramer B, Buffenstein R. The pancreas of the naked mole-rat (*Heterocephalus glaber*): an ultrastructural and immunocytochemical study of the endocrine component of thermoneutral and cold acclimated animals. *General and comparative endocrinology*. 2004; 139(3):206–14. doi: 10.1016/j.ygcen.2004.09.006. [PubMed: 15560867]
- Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer's disease: pathogen or protector? *Trends in molecular medicine*. 2005; 11(4):164–9. doi:10.1016/j.molmed.2005.02.008. [PubMed: 15823754]
- Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. *Nature medicine*. 2012; 18(2):291–5. doi:10.1038/nm.2613.
- Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. *Neuropathology and applied neurobiology*. 2007; 33(1):43–55. doi:10.1111/j.1365-2990.2006.00795.x. [PubMed: 17239007]
- Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, Tian Q, Wang XC, Chen XQ, Yang Y, Zhang JY, Wang Q, Xu H, Liao FF, Wang JZ. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104(9):3591–6. doi: 10.1073/pnas.0609303104. [PubMed: 17360687]
- Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. *The Journal of biological chemistry*. 1984; 259(8):5301–5. [PubMed: 6425287]
- Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. *Neurochemistry international*. 2011; 58(4):458–71. doi:10.1016/j.neuint.2010.12.023. [PubMed: 21215781]
- Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: involvement in Alzheimer's disease. *Ageing research reviews*. 2013; 12(1):289–309. doi:10.1016/j.arr.2012.06.003. [PubMed: 22742992]
- Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. *Journal of neuropathology and experimental neurology*. 1999; 58(2):188–97. [PubMed: 10029101]
- Nguyen U, Squaglia N, Boge A, Fung PA. The Simple Western: a gel-free, blot-free, hands-free Western blotting reinvention. *Nature Methods*. 2011:v–vi.
- Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron*. 2003; 39(3):409–21. [PubMed: 12895417]
- Oppenheim RW. Cell death during development of the nervous system. *Annual review of neuroscience*. 1991; 14:453–501. doi:10.1146/annurev.ne.14.030191.002321.
- Ozansoy MB, AN. Tauopathies: A distinct class of neurodegenerative diseases. *BJMG*. 2007; 10(2):3–14. doi:10.2478/v10034-008-0001-5.

- Pacheco CD, Elrick MJ, Lieberman AP. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. *Human molecular genetics*. 2009; 18(5):956–65. doi:10.1093/hmg/ddn423. [PubMed: 19074461]
- Peterson BL, Larson J, Buffenstein R, Park TJ, Fall CP. Blunted neuronal calcium response to hypoxia in naked mole-rat hippocampus. *PloS one*. 2012a; 7(2):e31568. doi:10.1371/journal.pone.0031568. [PubMed: 22363676]
- Peterson BL, Park TJ, Larson J. Adult naked mole-rat brain retains the NMDA receptor subunit GluN2D associated with hypoxia tolerance in neonatal mammals. *Neuroscience letters*. 2012b; 506(2):342–5. doi:10.1016/j.neulet.2011.11.042. [PubMed: 22155615]
- Rovelet-Lecrux A, Campion D. Copy number variations involving the microtubule-associated protein tau in human diseases. *Biochemical Society transactions*. 2012; 40(4):672–6. doi:10.1042/BST20120045. [PubMed: 22817714]
- Satoh Y, Endo S, Nakata T, Kobayashi Y, Yamada K, Ikeda T, Takeuchi A, Hiramoto T, Watanabe Y, Kazama T. ERK2 contributes to the control of social behaviors in mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011; 31(33):11953–67. doi:10.1523/JNEUROSCI.2349-11.2011. [PubMed: 21849556]
- Spillantini MG, Goedert M. Tau pathology and neurodegeneration. *Lancet neurology*. 2013; 12(6):609–22. doi:10.1016/S1474-4422(13)70090-5. [PubMed: 23684085]
- Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. *Experimental neurology*. 2001; 168(2):402–12. doi:10.1006/exnr.2001.7630. [PubMed: 11259128]
- Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. *The European journal of neuroscience*. 2007; 25(1):59–68. doi:10.1111/j.1460-9568.2006.05226.x. [PubMed: 17241267]
- Wirhth O, Bayer TA. Neuron loss in transgenic mouse models of Alzheimer's disease. *International journal of Alzheimer's disease* 2010. 2010 doi:10.4061/2010/723782.
- Yuan J, Lipinski M, Degtrev A. Diversity in the mechanisms of neuronal cell death. *Neuron*. 2003; 40(2):401–13. [PubMed: 14556717]
- Zahs KR, Ashe KH. 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? *Trends in neurosciences*. 2010; 33(8):381–9. doi:10.1016/j.tins.2010.05.004. [PubMed: 20542579]


Highlights

- Naked mole-rats express higher total and phosphorylated tau than 3xTgAD mice.
- Naked mole-rat tau increases in molecular weight during their extended development.
- Adult naked mole-rats express a unique, extremely large 88kDa brain tau.
- Dephosphorylated naked mole-rat tau is larger than human tau.
- Despite heavy phosphorylation, naked mole-rat tau maintains axonal localization.

```

Human 4R2N -----MAEPRQEFVEMEDHAGTYGLGDRKDQGGYTMHQDQEGDTPDAGLKESPLQTPTEDEGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTT
NMR 4R2N  MQGHLALRRREPLTRMAEPRQEFDMEDHAGDY-----TLLQDRDGDTEFGLKESPLQTPADGSEEPGSETSDAKSTPTAEVTAPLVDERAPGKQAAAQPHMEIPEGTT
          *****:***** *          *:***:*****:*****:*****:*****:*****:*****
Human 4R2N          HT7          CP13          Tau5
AEEAGIGDTPSLEDEAAGHVTAQRMVSKSKDGTGSDDKKAKGADGKT--KIATPRGAAPPGQKGGQANATRIPAKTTPAPKTPPSSGEPKSGDRSGYSSPGSPGTPGSRSRTPSLP
NMR 4R2N  AEEAGIGDTPNLEDAAGHVTAQRMISKGGKGTGNDKKAKGADGKTGTTTPRGAAPPGQKGAANATRIPAKTTPPKTSPSTGESAKSGDRSGYSSPGSPGTPGSRSRTPSLP
          *****:***:*****:***:*****:***** * :*****T***** ***** *:*** ** * *****T*****T*****
Human 4R2N          Tau5          RD3          RD4          RD3
TPPTREPKKVAVVTRPPKSPSSAKSRLQTAPVPMEDLKNVSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKP
NMR 4R2N  TPPTREPKKVAVVTRPPKSPSTKSRQLTAPVPMEDLKNVSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKP
          *****:*****:*****:*****:*****:*****:*****:*****:*****:*****:*****:*****:*****
          |<-----MTBD1----->|<-----MTBD2----->|<-----MTBD3----->
Human 4R2N          PHF1          Tau46
GGGQVEVKSEKLDKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSTGSIDMVDSPQLATLADEVSASLAKQGL
NMR 4R2N  GGGQVEVKSEKLDKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSTGSINMVDSLQLATLADEVSASLAKQGL
          *****:*****:*****:*****:*****:*****:*****:*****:*****:*****:*****:*****:*****
          --->|<-----MTBD4----->|
    
```

Fig. 1. Predicted naked mole-rat tau amino acid sequence is highly similar to human tau. The longest human brain tau protein splice variant (4R2N) aligned to a putative NMR tau protein indicates highest conservation at the carboxy-terminus with 100% identity at the functional microtubule-binding domain. Antibody epitopes used in this study are indicated by underline and bold typeface. Abbreviations: MTBD: Microtubule Binding Domain; HT7, Tau46 and Tau5: total tau antibodies; CP13: recognizes tau phosphorylated at Ser²⁰²/Thr²⁰⁵; PHF1 recognizes tau phosphorylated at Ser^{396/404}. Asterisk (*) indicates a fully conserved residue; colon (:) indicates conservation between groups of strongly similar properties; period (.) indicates conservation between groups of weakly similar properties. Amino acid numbering derived from human 4R2N splice variant.

**Fig. 2.**

Immunoblotting NMR brain homogenates using capillary electrophoresis with anti-human tau antibodies indicates high protein sequence homology and a unique NMR-expressed tau protein. (A) Naked mole-rat tau is immunoreactive to many well-characterized anti-tau antibodies. Based on human tau 4R2N sequence, Tau5 recognizes tau amino acids 210-229, a region immediately upstream of the microtubule binding domains; HT7 recognizes tau amino acids 159-163 within the proline rich domain; and Tau46 recognizes the far carboxy-terminal residues 401-441. RD3 and RD4 recognize tau proteins lacking (RD3) or expressing (RD4) microtubule-binding domain 2. Naked mole-rat tau is immunoreactive to all antibodies and appears as a much larger protein with slower electrophoretic mobility than either mouse (Ms) or human (Hu) tau. (B) Artificial immunoblots produced by capillary electrophoresis clearly illustrate that naked mole-rat tau undergoes a progressive shift in molecular weight during development. (C) The capillary electrophoresis electropherograms allow the acute discernment of distinct protein bands, which then generates the artificial blot shown in (B). Electropherograms indicate that neonatal naked mole-rat tau consists of two distinct bands: a prominent 62kDa band and a minor 72kDa band. During the first week of development, 72kDa tau expression increases to levels higher than 62kDa tau. By 3 months of age, 72kDa tau is heavily expressed and the emergence of a higher 88kDa band appears. By 1 year of age the high molecular weight 88kDa tau protein becomes the prominent tau protein with lower levels of 72kDa band remaining. Ms: mouse; Hu^{Rc}: Recombinant human tau 4R2N; Hu^{Tg}: transgenic mouse expressing wild type human tau, hTau (Andorfer, et al., 2003); Mo: months; Yr: year. *'s on electropherograms indicate 66, 90, and 116kDa respectively.






Fig. 3. The level of total tau expression significantly decreases during the NMR's long lifespan. (A) Artificial immunoblots produced by capillary electrophoresis graphically display total tau levels during the 30-year NMR lifespan. (B) Densitometric normalization of the electropherograms illustrate that total tau expression significantly decreases with NMR age (ANOVA, $p < 0.0001$). A significant change occurs throughout development with the highest expression during the first weeks of life, and by 6 months of age, total tau levels have significantly decreased (20.5% decrease; ANOVA, $p = 0.0496$) The level of total tau is well maintained from 6 months through early adulthood, and then significantly decreases in the 7-10 year-old cohort (ANOVA, $p = 0.0133$) and remains at this level throughout the remainder of the naked mole-rat lifespan. (C) Histological assessment of brain tau expression coincided with the capillary electrophoresis data revealing highest expression during the first weeks of life, a notable decrease at 6 months of age and then similar expression throughout the next two decades of life. Scale bar: 100 μ m.

**Fig. 4.**

Naked mole-rat tau phosphorylation partly contributes to the age-associated increase in molecular weight. (A) Adult and neonatal naked mole-rat tau is heavily phosphorylated at AD-associated epitope Ser^{396/404}. Naked mole-rat tau is most heavily phosphorylated during development and significantly changes with age (ANOVA, $p < 0.0001$). (B) Densitometric analysis indicates that PHF1 immunoreactivity decreases 32% after first week of life (ANOVA, $p = 0.0159$) and then drops significantly again between 20 days and 6 months (52% decrease; ANOVA, $p = 0.0081$) where levels then remain statistically similar throughout the rest of life. (C) Protein dephosphorylation with calf intestinal phosphatase (CIP) indicates that phosphorylation contributes to a large portion of the total molecular weight. While untreated tau from two-week old animals migrates as a 62, 66, 72 kDa triplet, dephosphorylated tau migrates as a single dense tau species ~60kDa immunoreactive to Tau1 but not PHF1. Recombinant human 4R2N tau migrates at 49kDa. Untreated two-year old animals express a prominent 88kDa tau band whereas dephosphorylation reveals a strong ~66kDa tau species immunoreactive to Tau1 but not PHF1. (D) In accord with capillary electrophoresis data, immunohistochemistry with phospho-Ser²⁰²/Thr²⁰⁵ tau antibody, CP13, shows highest levels of phospho-tau in development, a dramatic decrease at 6 months and with maintained levels throughout life in the cortex and hippocampal CA1. Scale bars: 100 μ m.

**Fig. 5.**

Alzheimer's disease-associated tau kinase protein levels remain in a narrow range throughout NMR life. (A) Artificial blots produced by capillary electrophoresis using antibodies against total tau kinases and their corresponding regulators. Shown are representative blots for Cdk5 and its co-activator, p35; total GSK3 β and inhibitory phosphorylation at residue Ser⁹; total ERK2 and its activating phosphorylation at Thr^{185/187} and corresponding GAPDH loading control. (B) Densitometry of Cdk5 and co-activator, p35, indicates stable expression throughout life. (C) Levels of GSK3 β significantly decrease during NMR lifespan (ANOVA, $p < 0.0001$). Specifically, GSK3 β is 30% higher during early neonatal development than in animals that have reached sexual maturity at 6-9 months (ANOVA, $p = 0.0008$); this adult level is maintained throughout life. Inhibitory phosphorylation at Ser⁹ significantly decreases throughout lifespan (ANOVA, $p = 0.0093$) whereby higher regulatory phosphorylation coincides with early neonatal development (0-1 week) than in the mature adults: 7-10 year olds (ANOVA, $p = 0.0087$), 12-15 year olds (ANOVA, $p = 0.0209$). (D) Total ERK2 levels remain stable throughout life; activating phosphorylation only differs in the oldest 30-year-old cohort (ANOVA, $p < 0.0001$).




Fig. 6. Adult NMRs express more HT7-tau and phospho-tau than 3xTg-AD mice with overt pathology. (A) Capillary electrophoresis of 7-year-old NMR and 15-month-old 3xTg-AD brain homogenates probed for total tau (HT7) and phospho-Ser²⁰²/Thr²⁰⁵ tau (CP13). (B) Corresponding densitometry indicates that NMRs express significantly higher HT7 total tau (***: unpaired t-test, $p < 0.0001$) and pSer²⁰²/Thr²⁰⁵ (**: unpaired t-test, $p = 0.0025$). (C) IHC with hippocampal tissue from representative NMR and 3xTg-AD mice revealed that NMRs maintain axonal tau expression in the mossy fibers but 3xTg-AD do not (CA3 inset, arrow points to mossy fibers). Instead tau from 3xTg-AD mice has inappropriately accumulated in neuronal soma and dendrites (CA1 inset).